Fresenius Medical Care AG & Co. KGaA (FMS)
| Market Cap | 11.77B |
| Revenue (ttm) | 19.40B |
| Net Income (ttm) | 673.41M |
| Shares Out | 586.83M |
| EPS (ttm) | 1.15 |
| PE Ratio | 16.31 |
| Forward PE | 9.92 |
| Dividend | $1.43 (7.13%) |
| Ex-Dividend Date | May 13, 2022 |
| Volume | 1,239,979 |
| Open | 19.93 |
| Previous Close | 19.44 |
| Day's Range | 19.81 - 20.10 |
| 52-Week Range | 12.79 - 34.65 |
| Beta | 0.88 |
| Analysts | Sell |
| Price Target | 18.88 (-5.88%) |
| Earnings Date | May 3, 2023 |
About FMS
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage rena... [Read more]
Financial Performance
In 2022, FMS's revenue was $19.40 billion, an increase of 10.10% compared to the previous year's $17.62 billion. Earnings were $673.41 million, a decrease of -30.53%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for FMS stock is "Sell." The 12-month stock price forecast is $18.88, which is a decrease of -5.88% from the latest price.
News
Fresenius Medical's (FMS) Q4 Earnings and Revenues Beat
Fresenius Medical's (FMS) fourth-quarter revenues benefit from strong performance across all segments, especially in the North America and Asia-Pacific regions. However, rising costs hurt margins.
Fresenius Medical Care takes action to close global health gaps, signs "Zero Health Gaps" Pledge at the World Economic Forum
WALTHAM, Mass. , Jan. 20, 2023 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps P...
Bear of the Day: Fresenius Medical (FMS)
Profit estimates are moving in the wrong direction.
Fresenius Medical's (FMS) Q3 Earnings and Revenues Top
Fresenius Medical's (FMS) third-quarter revenues benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
Fresenius Medical cuts outlook on slower recovery, rising costs
Kidney dialysis provider Fresenius Medical Care (FMC) on Sunday revised down its forecast for 2022, expecting net income to decline this year, dragged down by rising labour costs and a slower than exp...
Investor Elliott has taken stake in Germany's Fresenius -Bloomberg
Elliott Investment Management has taken a stake in Fresenius SE , seeking to potentially break up the diversified healthcare company, Bloomberg cited people familiar with the matter as saying.
Fresenius Medical Care partners with National Kidney Foundation Malaysia in kidney health initiative
HONG KONG--(BUSINESS WIRE)-- #CKDprevention--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today signed a memorandum of understandi...
Fresenius Medical (FMS) Robust Product Portfolio Drives Growth
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovations CytoSorb will b...
Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
Fresenius now expects lower revenue, earnings in the second half, citing wage inflation and staff shortages in North America
Shares of Fresenius Medical Care tumbled 13.7% in premarket trading on Thursday after telling investors to expect lower-than-expected revenue and net income in the second half of the year. The company...
Fresenius cuts FY outlook on higher costs at dialysis business
German healthcare group Fresenius SE cut its full-year earnings outlook due to cost inflation at its kidney dialysis subsidiary Fresenius Medical Care (FMC), it said late on Wednesday.
After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i...
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius (FMS) Faces Fraud Accusation From US Government
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures...
Highmark Interactive Inc. Announces Collaboration with Renal Research Institute to Identify Potential Biomarkers of Brain Injury in Hemodialysis Patients
The Renal Research Institute will include the Highmark digital assessment suite into its clinical research of people receiving in-center hemodialysis treatment. TORONTO, ON / ACCESSWIRE / June 20, 202...
Fresenius Medical Care Celebrates Diversity and Unity of a Global Nurse Workforce
HONG KONG--(BUSINESS WIRE)-- #healthcare--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care'...
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
Fresenius Medical Care Launches My Reason® Campaign to Enroll Patients in Groundbreaking Renal-focused Genomic Registry
Goal of 100,000 Participants Within Five Years to Help Scientists Better Understand Genetic Variations in Patients with Chronic Kidney Disease WALTHAM, Mass. , April 13, 2022 /PRNewswire/ -- Fresenius...
Fresenius Medical Care Appoints Dr. Amaka Eneanya as Head of Strategy and Operations for Company's Global Medical Office
WALTHAM, Mass. , April 5, 2022 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced today the appointment of not...
Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care
Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.
How Fresenius Medical Care's Superhero Is Helping Bridge the Knowledge Gap to Better Kidney Health
HONG KONG--(BUSINESS WIRE)-- #chronickidneydisease--Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has today announced the social me...
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.